Zoryve (roflumilast) cream 0.05%
Arcutis Biotherapeutics (ARQT)
Decision dateFeb 23, 2027
100 days away
Marketer take
Extending down to infants as young as 3 months would put a nonsteroidal brand in pediatricians' and pediatric dermatologists' offices, where parent-facing steroid-sparing messaging matters.
- Sponsor company
- Arcutis Biotherapeutics (ARQT)
- Indication
- Atopic dermatitis in infants down to 3 months (sNDA)
- Therapeutic area
- Dermatology
- Event
- PDUFA target action date
- Date
- Feb 23, 2027
- Status
- Upcoming
- Source
- company press release
- Last verified
- Nov 15, 2026
Dates and status come from the linked public source as of the last verified date. Spot an error or have an update?